Compare AstraZeneca plc (AZN) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Lithium Americas Corp — how do they compare? AstraZeneca plc trades at $169.31 (market cap $253.13B), while Lithium Americas Corp trades at $3.09 (market cap $1.11B). The key difference: AstraZeneca plc is far larger — about 228× Lithium Americas Corp's market cap, and AstraZeneca plc pays a 1.92% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| AZN | LAC | |
|---|---|---|
Market Cap | $253.13B | $1.11B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $10.05 |
52-Week Low | $137.44 | $2.55 |
Enterprise Value | $279.37B | $1.22B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Lithium Americas (LAC) trades at $3.14, down 5.42% on the day, reflecting ongoing market pressure despite recent earnings beats. The stock shows mixed signals with bearish technical indicators but bullish oscillators suggesting potential oversold conditions. Fundamentally, the company remains in development phase with negative profitability metrics (ROE -11.35%, net loss $122M in 2025) but maintains analyst support for its Thacker Pass lithium project development.
LAC presents a high-risk, high-reward opportunity with significant execution risk on its capital-intensive lithium project. While analyst consensus targets $6.25 (99% upside), investors face dilution risk from ongoing financing needs and operational challenges. The stock's appeal hinges on successful project development and lithium market recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
